What type of study is this?

This is a Human Clinical Trial study (also classified as: Pre-Registered Trial).

What question did this study set out to answer?

Evaluate the efficacy and safety of tislelizumab maintenance therapy after autologous stem cell transplantation in relapsed or refractory DLBCL.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Evaluate the efficacy and safety of tislelizumab maintenance therapy after autologous stem cell transplantation in relapsed or refractory DLBCL.
Multicenter, randomized controlled, prospective clinical trial.
150 patients with R/R DLBCL aged 18–65 were planned for enrollment.
Patients randomized to receive tislelizumab or no intervention post-ASCT.
2-year progression-free survival rate was 94.4% in tislelizumab group vs. 72.2% in control (p=0.012).
2-year overall survival rate was 100.0% in tislelizumab group vs. 83.7% in control (p=0.062).
Only one grade 3 adverse event reported, with no treatment discontinuations or dose reductions.

No takes yet. Share an insight, caveat, or question.

Randomized trial improved progression-free survival in relapsed/refractory DLBCL patients, suggesting tislelizumab is a safe maintenance option.

Pengpeng Xu (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial improved progression-free survival in relapsed/refractory DLBCL patients, suggesting tislelizumab is a safe maintenance option.